Durable responses with the metronomic rituximab and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide regimen in elderly patients with recurrent mantle cell lymphoma Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Lymphoma, Mantle-Cell

abstract

  • RT-PEPC had significant and durable activity in MCL with manageable toxicity and maintained QoL. Novel, low-intensity approaches warrant further evaluation, potentially as initial therapy in elderly patients.

publication date

  • June 2010

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3004744

Digital Object Identifier (DOI)

  • 10.1002/cncr.25055

PubMed ID

  • 20235190

Additional Document Info

start page

  • 2655

end page

  • 64

volume

  • 116

number

  • 11